Insider Transactions in Q1 2025 at Adaptimmune Therapeutics PLC (ADAP)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 17
2025
|
Adrian Rawcliffe Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
30,601
-40.84%
|
$0
$0.58 P/Share
|
|
Jan 17
2025
|
William C Bertrand Jr Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
5,584
-42.65%
|
$0
$0.58 P/Share
|
|
Jan 17
2025
|
John Lunger Chief Patient Supply Officer |
SELL
Open market or private sale
|
Direct |
5,584
-42.65%
|
$0
$0.58 P/Share
|
|
Jan 17
2025
|
Elliot Norry Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,584
-42.65%
|
$0
$0.58 P/Share
|
|
Jan 15
2025
|
Adrian Rawcliffe Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
29,096
-41.17%
|
$0
$0.57 P/Share
|
|
Jan 15
2025
|
William C Bertrand Jr Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
9,803
-41.61%
|
$0
$0.57 P/Share
|
|
Jan 15
2025
|
John Lunger Chief Patient Supply Officer |
SELL
Open market or private sale
|
Direct |
9,803
-41.61%
|
$0
$0.57 P/Share
|
|
Jan 15
2025
|
Elliot Norry Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
9,803
-41.61%
|
$0
$0.57 P/Share
|
|
Jan 15
2025
|
Cintia Piccina Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
12,991
-41.36%
|
$0
$0.57 P/Share
|
|
Jan 13
2025
|
Adrian Rawcliffe Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
30,473
-41.21%
|
$0
$0.59 P/Share
|
|
Jan 13
2025
|
William C Bertrand Jr Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
9,739
-41.99%
|
$0
$0.59 P/Share
|
|
Jan 13
2025
|
John Lunger Chief Patient Supply Officer |
SELL
Open market or private sale
|
Direct |
9,739
-41.99%
|
$0
$0.59 P/Share
|
|
Jan 13
2025
|
Elliot Norry Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
12,392
-41.78%
|
$0
$0.59 P/Share
|